Halberd announced that preliminary testing of its extracorporeal laser irradiation methodologies completely eradicated Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF).
Halberd Corporation announced that preliminary testing of its extracorporeal laser irradiation methodologies completely eradicated Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF). IL-1 is tied to various diseases, from autoimmune disorders to multiple sclerosis (MS) and Alzheimer’s disease.
This study followed an announcement on December 6 that they had completed verification tests on eliminating Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic CSF. It uses the same technology. TNF-alpha is an inflammatory cytokine that contributes to Alzheimer’s, as well as PTSD/Chronic Traumatic Encephalopathy (CTE) and obesity.
The company is also evaluating the technology on several other diseases, including COVID-19 and other viral infections.
“Interleukin-1 is associated with many diseases, including critically life-threatening and quality of life deterioration afflictions,” said Mitchell S. Felder, Halberd’s chief technology officer. “The ability to control the levels of IL-1 in cerebral spinal fluid gives us an effective tool in obstructing the progression of various neurological diseases, especially Alzheimer’s, as well as other diseases with the same antigens and/or cytokines.”
The company’s long-term plans will focus on eradicating other pathogens from CSF and blood associated with Alzheimer’s, Parkinson’s disease, Lou Gehrig’s disease (amyotrophic lateral sclerosis or ALS), epilepsy and obesity. At this time, they have completed testing on IL-6, TNF-alpha, and phosphorylated tau, which is associated with Alzheimer’s and other dementias. They are also testing it on eradicating IL-1, IL-12, beta amyloid, IL-2, IL-4, Tau and glutamate.
“We have now demonstrated that through our patented and patent pending extracorporeal laser irradiation methodology that we can eradicate targeted disease antigens and inflammatory cytokines associated with neurodegenerative diseases,” said William A. Hartman, Halberd’s chairman, president and chief executive officer. “We have no doubt that our technology will also be successful in eliminating the balance of the inflammatory cytokines and excitatory neurotransmitters identified in our test plan.”
Extracorporeal refers to “outside the body.” The technologies Halberd is focusing on are a kind of dialysis treatment, where the blood or fluids are filtered to eliminate specific types of pathogens or molecules. For example, its approach to COVID-19 involves treating the patient’s blood by introducing one or more antibody-antigen complexing agents that bind to COVID-19 target antigens linked to inflammatory cytokine storms, then removing the antibody-antigen complex using a variety of methods, such as dialysis, nano-lasers or molecular adsorbent recirculating systems (MARS).
In November 2021, the company filed a non-provisional patent application for treating COVID-19 extracorporeally via exposure to radio frequency waves. It describes the continuous flow of the treatment process as similar to dialysis and introduced a proprietary SARS-CoV-2 antibody attached to a gold coated iron nanoparticle into the blood as it is removed from the patient.
At the time, Hartman said, “The technology developed in support of this patent application has been key in our related work on developing treatments for Alzheimer’s disease, PTSD, Chronic Traumatic Encephalopathy (CTE), Traumatic Brain Injury (TBI) and many other neurological diseases, as well as bacteriological (e.g., E. Coli) and viral infections, particularly those which have developed antibiotic resistance. Halberd’s primary focus will remain on neurological diseases, but this patent is intended to enhance Halberd’s value in the overall scientific community.”
